Call for Abstract
Scientific Program
2nd International Conference on Antimicrobial Agents and Chemotherapy, will be organized around the theme “Innovative Cancer Therapy for Tomorrow”
Chemotherapy 2017 is comprised of 11 tracks and 51 sessions designed to offer comprehensive sessions that address current issues in Chemotherapy 2017.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Antimicrobial chemotherapy is the clinical application of antimicrobial agents to treat infectious disease. It is a highly valued medical science that has shaped modern humanity in a phenomenol fashion. Chemotherapy is the use of chemicals against invading organisms. It is used both for the treatment of cancer and infection. Antimicrobial chemotherapy thus act by interfering with cell wall synthesis, plasma membrane integrity, nucleic acid synthesis, ribosomal function and folate synthesis.
- Track 1-1Bacterial infections & Antibacterial Medications
- Track 1-2Antimicrobial Prophylaxis: - Mechanism of Action
- Track 1-3Pharmaceutical antimicrobials versus Non-Pharmaceutical Antimicrobials
- Track 1-4Anti-Fungal Chemotherapy
- Track 1-5Antiviral Chemotherapy and AIDS
- Track 1-6Natural Antimicrobial Chemotherapeutic Agents
Chemotherapy is a kind of cancer treatment that uses drug to destroy cancer cells. Chemotherapy works by slowing down the growth of cancer cells which grow and divide quickly. But it can also harm healthy cells that divide too quickly. Chemotherapy process can cure cancer, control cancer and ease cancer symptoms.
- Track 2-1Chemotherapeutic advancement for treatment of Lymphoma
- Track 2-2Ovarian Cancer and Chemotherapy
- Track 2-3Dendritic Cell Cancer and its Therapeutics
- Track 2-4Breast Cancer and Chemotherapy
- Track 2-5Chemotherapeutic advancement for treatment of Leukemia
- Track 2-6Thyroid Cancer and its Therapeutics
Chemotherapy encompasses a wide variety of therapy treatments. Terms such as "adjuvant," "neoadjuvant," "consolidation," and "palliative" often add to the confusion surrounding chemotherapy if not properly defined and explained. The purpose of this page is to increase the level of understanding about various chemotherapy protocols currently used.
- Track 3-1Palliative chemotherapy
- Track 3-2Adjuvant chemotherapy
- Track 3-3HAMLET chemotherapy
- Track 3-4Neoadjuvant chemotherapy
- Track 3-5Induction chemotherapy
- Track 3-6Consolidation chemotherapy
- Track 3-7Maintenance chemotherapy
- Track 3-8First line chemotherapy
- Track 3-9Second line chemotherapy
Chemotherapy protocols strive to maximize the elimination of cancer cells while minimizing the negative effects that these protocols have on healthy cells. Much progress in developing successful chemotherapy protocols has been made, including the identification of many different types of cancer and the corresponding development of effective chemotherapy protocol solutions. But there is still much work to be done.
- Track 4-1Radiopharmaceuticals and Cancer
- Track 4-2Chemotherapy protocols in the development of novel drug for cancer treatment
- Track 4-3Advancement in Chemotherapy Resistant Lymphoma
- Track 4-4Distress screening process in cancer treatment for cancer patients
Chemotherapeutic techniques have a range of side-effects that depend on the type of medications used. The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the mouth, stomach, and intestines. Chemotherapy-related toxicities can occur acutely after administration, within hours or days, or chronically, from weeks to years.
- Track 5-1Immunosuppression and myelosuppression
- Track 5-2Gastrointestinal distress
- Track 5-3Alopecia
- Track 5-4Teratogenicity
- Track 5-5Infertility
Nano medicine is the medical application of nanotechnology. Nano medicine ranges from the medical applications of nanomaterial’s and biological devices, to Nano electronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Limitations to conventional cancer chemotherapy include drug resistance, lack of selectivity, and lack of solubility. Nanoparticles have the potential to overcome these problems.
- Track 6-1Nano scale biomedical devices and Cancer
- Track 6-2Role of NCI in developing nanotechnology devices for Cancer
- Track 6-3Novel Drug Delivery Systems for treatment of Cancer
Clinical trials are experiments done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. Of every 5,000 cancer molecules identified in the laboratory, about 250 will enter pre-clinical testing. Of this 250, fewer than 10 are tested in clinical trials and on average only one will be approved by regulatory authorities. The process of bringing a new treatment from the research stage (laboratory) to clinic is estimated to take between 10–13 years.
- Track 7-1Novel approaches in the field of Radiation Therapy
- Track 7-2Advantages and Disadvantages of clinical trials in Cancer treatment
- Track 7-3Role of FDA in the development of clinical trials related to Cancer
- Track 7-4Role in disease treatment and applications
- Track 7-5Clinical trial phases
Antimicrobial resistance (AMR) is when a microbe evolves to become more or fully resistant to antimicrobials which previously could treat it. This broader term also covers antibiotic resistance, which applies to bacteria and antibiotics. Resistant microbes are increasingly difficult to treat, requiring alternative medications or higher doses—which may be more costly or more toxic. Microbes resistant to multiple antimicrobials are called multidrug resistant (MDR); or sometimes superbugs.
- Track 8-1Genetic mutation and antimicrobial resistance
- Track 8-2Monitoring methods to prevent antimicrobial resistance
- Track 8-3Microbial involved in antimicrobial resistance
- Track 8-4Application of antimicrobial resistance
Biologic Response Modifiers (BRM), also called immunotherapy, is a type of treatment that mobilizes the body's immune system to fight cancer. The therapy mainly consists of stimulating the immune system to help it do its job more effectively. Tumor Vaccines also work to stimulate the body's immune system.
- Track 9-1Anti cancer drugs and alternative medicine of cancer
- Track 9-2Monoclonal antibodies and cancer treatment
- Track 9-3Immunotherapy agents and cervical intraepithelial neoplasia
- Track 9-4Human Papilloma Virus related cancer
- Track 9-5Immunological developments and cancer
Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the multiple drug resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies.
- Track 10-1Tumor heterogeneity
- Track 10-2Mechanisms of acquired antineoplastic resistance
- Track 10-3Genetic markers for drug sensitivity and resistance
- Track 10-4Genetic approaches to overcome drug resistance
A global platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable business meeting place for engaging people in constructive discussions, evaluation and execution of promising business ideas. Through Antimicrobial agents and chemotherapy 2016, an investor could be able to find out the highest potential investment opportunities in the field of cancer. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start or expand their business.